(11/12/2020) The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes1.
By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche’s strategy of integrated Personalised Diabetes Management (iPDM).


Basel, 11 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it is partnering with the French MedTech company Diabeloop to advance the management of insulin pump therapy, creating new opportunities to lower the burden of constant insulin dose adjustment for people with diabetes and to improve therapy outcomes1. The partnership marks Roche’s first step in the field of automated insulin delivery (AID) representing a milestone in Roche’s strategy of integrated Personalised Diabetes Management (iPDM). By building on its own strengths and expanding its offering through the partnership with Diabeloop, Roche embraces its vision to bring innovation to people with diabetes helping them to experience true relief.

“Everybody at Roche Diabetes Care is excited about the new partnership with Diabeloop. The technology of Diabeloop, based on a self-learning algorithm, is unique. We are convinced that the potential of the hybrid closed-loop systems will contribute to a more efficient and personalised approach of diabetes management,” said Marcel Gmuender, Global Head of Roche Diabetes Care. “For more than three decades, we have been committed to supporting people with diabetes with a range of different insulin pump technologies. Throughout the years, we have always aimed to give people with diabetes choice, so that they can select the best therapy solutions to suit their needs. Together with Diabeloop, we are again expanding the choice of options available to people with diabetes, by embarking on our journey of automated insulin delivery.”

“Reliable insulin delivery is a critical component in Diabeloop’s hybrid closed-loop systems embedding therapeutic artificial intelligence. The accuracy and reliability of Roche’s insulin pump portfolio perfectly fits our vision to personalise therapy to the physiology and lifestyle of people with diabetes, helping them to spend less time managing diabetes while improving time in range1,” said Erik Huneker, Diabeloop founder and co-CEO. « We are looking forward to partnering with Roche and work together to individualise diabetes management,” concluded Marc Julien, co-CEO at Diabeloop.

201211-diabeloop-roche-cooperation

About Roche Diabetes Care

Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.

Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief. Since 2017, mySugr, one of the most popular diabetes management apps, is part of Roche Diabetes Care. For more information, please visit www.rochediabetes.com, www.accu-chek.com and www.mysugr.com.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. Reference

[1] Benhamou PY, Franc S, Reznik Y, et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digital Health. 2019;1: e17–25

For more information please contact: – Soo-Jin Pak (soo-jin.pak@roche.com) – Yvette Petillon (yvette.petillon@roche.com)

Nous contacter

We're not around right now. But you can send us an email and we'll get back to you, asap.